文献速递血管炎

硫唑嘌呤与甲氨蝶呤治疗嗜酸性肉芽肿性多血管炎:一项单中心回顾性研究

Azathioprine vs methotrexate in eosinophilic granulomatosis with polyangiitis: a monocentric retrospective study.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该单中心回顾性研究纳入57例嗜酸性肉芽肿性多血管炎患者,比较硫唑嘌呤(AZA)与甲氨蝶呤(MTX)作为一线诱导或二线维持治疗的疗效、安全性及减少激素用量作用。两组缓解率无显著差异,MTX一线治疗早期缓解(R2)更多,MTX二线维持治疗累积糖皮质激素剂量更低,但MTX不良事件更多。

要点

  • 一线治疗中MTX较AZA在前6个月更常达到R2缓解(54% vs 12%,P=0.04)。
  • 二线维持治疗中MTX组5年累积糖皮质激素剂量低于AZA组(6 g vs 10.7 g,P=0.03)。
  • MTX不良事件发生率高于AZA(66% vs 30%,P=0.004),但两组停药率无差异。

核心结论

  • MTX和AZA治疗均有较高比例患者达到缓解;MTX一线治疗缓解更早且激素剂量更低,MTX二线维持治疗减少激素用量效果更好。

研究设计与样本

  • 单中心回顾性研究,收集57例嗜酸性肉芽肿性多血管炎患者数据,按治疗分为四组:MTX/AZA作为一线药物(MTX1/AZA1)用于非重症疾病,或作为二线维持治疗(MTX2/AZA2)用于既往接受环磷酰胺/利妥昔单抗的重症疾病。

主要发现

  • 各组R1缓解率无显著差异:MTX1组63% vs AZA1组75%,P=0.53;MTX2组91% vs AZA2组71%,P=0.23。
  • MTX1组前6个月达到R2的比例高于AZA1组(54% vs 12%,P=0.04);AZA1组前18个月无患者达到R3,MTX1组为35%(P=0.07)。
  • MTX2组5年累积糖皮质激素剂量低于AZA2组(6 g vs 10.7 g,P=0.03)。
  • MTX组不良事件发生率高于AZA组(66% vs 30%,P=0.004),但两组停药率无差异。
  • 至首次复发时间无差异,但AZA2组发生哮喘/耳鼻喉复发的患者比例低于MTX2组(23% vs 64%,P=0.04)。

关键数值与推荐

  • 缓解定义:R1为BVAS=0;R2为BVAS=0且泼尼松≤5 mg/天;R3(MIRRA定义)为BVAS=0且泼尼松≤3.75 mg/天。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To analyse the effectiveness, safety and steroid-sparing effect of AZA and MTX as induction of remission and maintenance treatment in eosinophilic granulomatosis with polyangiitis. METHODS: We retrospectively collected data from 57 patients divided into four groups according to treatment: MTX/AZA as first-line agents (MTX1/AZA1) in non-severe disease or as second-line maintenance therapy (MTX2/AZA2) in severe disease previously treated with CYC/rituximab. During the first 5 years of treatment with AZA/MTX we compared the groups according to: remission rate [defined as R1: BVAS = 0; R2: BVAS = 0 with prednisone ≤5 mg/day; R3 (MIRRA definition): BVAS = 0 with prednisone ≤3.75 mg/day], persistence on therapy, cumulative glucocorticoid (GC) dose, relapse and adverse events (AEs). RESULTS: There were no significant differences in remission rates (R1) in each group (63% in MTX1 vs 75% in AZA1, P = 0.53; 91% in MTX2 vs 71% in AZA2, P = 0.23). MTX1 allowed R2 more frequently in the first 6 months compared with AZA1 (54% vs 12%, P = 0.04); no patients receiving AZA1 achieved R3 up to the first 18 months (vs 35% in MTX1, P = 0.07). The cumulative GC dose was lower for MTX2 vs AZA2 (6 g vs 10.7 g at 5 years, P = 0.03). MTX caused more AEs compared with AZA (66% vs 30%, P = 0.004), without affecting the suspension rate. No differences emerged in time-to-first relapse, although fewer patients treated with AZA2 had asthma/ENT relapses (23% vs 64%, P = 0.04). CONCLUSION: A significant proportion of patients achieved remission with both MTX and AZA. MTX1 had an earlier remission on a lower GC dose but MTX2 had a better steroid-sparing effect.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Milanesi A, Delvino P, Quaglini S, et al. Azathioprine vs methotrexate in eosinophilic granulomatosis with polyangiitis: a monocentric retrospective study. Rheumatology (Oxford). 2024. PMID: 37326880. doi:10.1093/rheumatology/kead302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。